Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Laura Cicconi, Jad Othman, Alessandra Spagnoli, Enrico Attardi, Eleonora De Bellis, Pilar Lloret Madrid, Tamara Castaño, Juan Miguel Bergua Burgues, Arianna Savi, Ida Carmosino, Roberta Mazzarella, Armando Mena Duran, Mar Tormo, Susana Vives, Emília Cortesão, Fernanda Trigo, Mercedes Colorado, Lorenzo Algarra, Olga Salamero, José Antonio Pérez-Simón, Esther Perez, ANA Yurena Oliva Hernandez, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Claudia Lucia Scossa Melo, Cristina Gil, Marta Valero Núñez, Luis Felipe Casado Montero, Teresa Olave, Maria Vidriales Vicente, Carla Amigo, Irene Navarro Vicente, Cristian Escolano Escobar, Pilar Herrera Puente, Kenny Galvez, Rosalia Riaza Grau, Annalina Piccioni, Davide Facchinelli, Enrico Santinelli, Raffaele Palmieri, Giovanni Luzi, Monica Piedimonte, Sabrina Mariani, Luana Fianchi, Carmela Gurrieri, Ilaria Tanasi, Davide Lanzarotto, Fabio Guolo, Salvatore Perrone, Elisabetta Todisco, Anjum Khan, Victoria Campbell, Maria Teresa Voso, Daniela Cilloni, Adriano Venditti, Roberto Latagliata, Richard Dillon, Massimo Breccia, Luca Maurillo, Susanna Fenu, Alessandro Pulsoni, Pau Montesinos

Blood (2025) 146 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2025-3437

Published: 2025

Journal Articles

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Mike Dennis, Jad Othman, Joanna Canham, Ian Thomas, Sean Johnson, Nick Telford, Beth Harrison, Jeyaprakash Ramachandran, James Cavenagh, Claire Arnold, Claus Marcher, Richard Kelly, Mhairi Copland, Alan Burnett, Richard Dillon, Nigel Russell

Blood (2025) 146 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2025-3435

Published: 2025

Journal Articles

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Blood (2025) 146 (Supplement 1): 3429.

https://doi.org/10.1182/blood-2025-3429

Published: 2025

Journal Articles

Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)

Blood (2025) 146 (Supplement 1): 217.

https://doi.org/10.1182/blood-2025-217

Published: 2025

Journal Articles

Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries

Blood (2025) 146 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2025-1739

Published: 2025

Journal Articles

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

Blood (2025) 146 (Supplement 1): 346.

https://doi.org/10.1182/blood-2025-346

Published: 2025

Journal Articles

FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials

Blood (2025) 146 (Supplement 1): 345.

https://doi.org/10.1182/blood-2025-345

Published: 2025

Journal Articles

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Blood (2025) 146 (Supplement 1): 343.

https://doi.org/10.1182/blood-2025-343

Published: 2025

Journal Articles

Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial

Blood (2025) 146 (Supplement 1): 879.

https://doi.org/10.1182/blood-2025-879

Published: 2025

Journal Articles

First results from the Phase 1 study of APL-4098, an oral potent GCN2 inhibitor for the treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and Myelodysplastic Syndromes (MDS)/AML

Shaun Fleming, Shuhying Tan, Mridula Mokoonlall, Andrew McQuillan, Paul Yeh, Hun Chuah, Rueben Amofa, Laurie Green, Paola Paganoni, Misba Beerahee, Brian Hamilton, Nadine Clemo, Sanjay Aggarwal, Richard Dillon

Blood (2025) 146 (Supplement 1): 6945.

https://doi.org/10.1182/blood-2025-6945

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Blood (2025) 146 (Supplement 1): 5278.

https://doi.org/10.1182/blood-2025-5278

Published: 2025

Journal Articles

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Blood (2025) 146 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2025-1662

Published: 2025

Journal Articles

Induction chemotherapy and molecular MRD influence outcomes in KMT2A -rearranged AML

Blood (2025) 146 (15): 1862–1867.

https://doi.org/10.1182/blood.2025029556

Published: 2025

Includes: Supplemental data

Journal Articles

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Blood (2025) 145 (2): 234–243.

https://doi.org/10.1182/blood.2024026186

Published: 2025

Includes: Supplemental data

Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I. Ravikumar, Jad Othman, Jenny O’Nions, Daniel T. Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard Dillon, Joshua F. Zeidner, Daniel A. Pollyea

Blood (2024) 144 (26): 2788–2792.

https://doi.org/10.1182/blood.2024026925

Published: 2024

Includes: Supplemental data

Journal Articles

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

Blood (2024) 144 (24): 2554–2557.

https://doi.org/10.1182/blood.2024026605

Published: 2024

Includes: Supplemental data

Journal Articles

Optimising Therapy in FLT3 -Mutated Acute Myeloid Leukaemia

Joanna Canham, Angela Casbard, Sylvie D Freeman, Nicola Potter, Abin Thomas, Amanda Gilkes, Sean Johnson, Lucy Marsh, Jane Leahy, Hayley Timmins, Richard Dillon, Steve Knapper

Blood (2024) 144 (Supplement 1): 4191.1.

https://doi.org/10.1182/blood-2024-204975

Published: 2024

Journal Articles

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Blood (2024) 144 (Supplement 1): 845.

https://doi.org/10.1182/blood-2024-201097

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)

Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial

First results from the Phase 1 study of APL-4098, an oral potent GCN2 inhibitor for the treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and Myelodysplastic Syndromes (MDS)/AML

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Induction chemotherapy and molecular MRD influence outcomes in KMT2A -rearranged AML

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

Optimising Therapy in FLT3 -Mutated Acute Myeloid Leukaemia

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only